BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24531137)

  • 1. Survivin as a preferential target for cancer therapy.
    Mobahat M; Narendran A; Riabowol K
    Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin as a Potential Target for Cancer Therapy.
    Soleimanpour E; Babaei E
    Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
    Kelly RJ; Lopez-Chavez A; Citrin D; Janik JE; Morris JC
    Mol Cancer; 2011 Apr; 10():35. PubMed ID: 21470426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin in survival of hepatocellular carcinoma.
    Su C
    Cancer Lett; 2016 Sep; 379(2):184-90. PubMed ID: 26118774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treat cancers by targeting survivin: just a dream or future reality?
    Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
    Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.
    Santarelli A; Mascitti M; Lo Russo L; Sartini D; Troiano G; Emanuelli M; Lo Muzio L
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of apoptosis: clinical implications in cancer.
    Mohamed MS; Bishr MK; Almutairi FM; Ali AG
    Apoptosis; 2017 Dec; 22(12):1487-1509. PubMed ID: 29067538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
    Shahar N; Larisch S
    Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
    Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
    Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting survivin for therapeutic discovery: past, present, and future promises.
    Peery RC; Liu JY; Zhang JT
    Drug Discov Today; 2017 Oct; 22(10):1466-1477. PubMed ID: 28577912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
    Lee EY; Gong EY; Shin JS; Moon JH; Shim HJ; Kim SM; Lee S; Jeong J; Gong JH; Kim MJ; Lee DH; Park YS; Shin J; Hong SW; Kim YS; Jin DH
    Toxicol In Vitro; 2018 Feb; 46():229-236. PubMed ID: 28947240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-pathologic relevance of Survivin splice variant expression in cancer.
    Necochea-Campion Rd; Chen CS; Mirshahidi S; Howard FD; Wall NR
    Cancer Lett; 2013 Oct; 339(2):167-74. PubMed ID: 23791888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring survivin expression in cancer: implications for prognosis and therapy.
    Santa Cruz Guindalini R; Mathias Machado MC; Garicochea B
    Mol Diagn Ther; 2013 Dec; 17(6):331-42. PubMed ID: 23912862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors.
    Vucic D
    Curr Cancer Drug Targets; 2008 Mar; 8(2):110-7. PubMed ID: 18336193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of the survivin gene.
    Boidot R; Végran F; Lizard-Nacol S
    Mol Biol Rep; 2014 Jan; 41(1):233-40. PubMed ID: 24197699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
    Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of apoptosis and roles in cancer development and treatment.
    Goldar S; Khaniani MS; Derakhshan SM; Baradaran B
    Asian Pac J Cancer Prev; 2015; 16(6):2129-44. PubMed ID: 25824729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.